JP2012522754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522754A5 JP2012522754A5 JP2012502694A JP2012502694A JP2012522754A5 JP 2012522754 A5 JP2012522754 A5 JP 2012522754A5 JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012502694 A JP2012502694 A JP 2012502694A JP 2012522754 A5 JP2012522754 A5 JP 2012522754A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- disease
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157303 | 2009-04-03 | ||
| EP09157303.0 | 2009-04-03 | ||
| PCT/EP2010/054418 WO2010115843A2 (en) | 2009-04-03 | 2010-04-01 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015129383A Division JP2015214559A (ja) | 2009-04-03 | 2015-06-29 | 薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522754A JP2012522754A (ja) | 2012-09-27 |
| JP2012522754A5 true JP2012522754A5 (enExample) | 2013-05-09 |
| JP5810076B2 JP5810076B2 (ja) | 2015-11-11 |
Family
ID=42269736
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502694A Active JP5810076B2 (ja) | 2009-04-03 | 2010-04-01 | 薬学的組成物 |
| JP2015129383A Withdrawn JP2015214559A (ja) | 2009-04-03 | 2015-06-29 | 薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015129383A Withdrawn JP2015214559A (ja) | 2009-04-03 | 2015-06-29 | 薬学的組成物 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8647631B2 (enExample) |
| EP (2) | EP2413957B1 (enExample) |
| JP (2) | JP5810076B2 (enExample) |
| KR (2) | KR20150041203A (enExample) |
| CN (2) | CN102946899B (enExample) |
| AU (1) | AU2010233856B2 (enExample) |
| BR (1) | BRPI1015088B1 (enExample) |
| CA (1) | CA2757345C (enExample) |
| CL (2) | CL2011002457A1 (enExample) |
| CO (1) | CO6390113A2 (enExample) |
| CR (1) | CR20110509A (enExample) |
| DK (2) | DK3097925T3 (enExample) |
| EC (1) | ECSP11011367A (enExample) |
| ES (2) | ES2595371T3 (enExample) |
| HU (2) | HUE044981T2 (enExample) |
| IL (1) | IL215451A (enExample) |
| MA (1) | MA34120B1 (enExample) |
| MX (1) | MX2011010353A (enExample) |
| MY (1) | MY171300A (enExample) |
| NZ (1) | NZ595856A (enExample) |
| PL (2) | PL3097925T3 (enExample) |
| PT (2) | PT2413957T (enExample) |
| RU (1) | RU2582916C2 (enExample) |
| SG (1) | SG175037A1 (enExample) |
| SI (2) | SI2413957T1 (enExample) |
| UA (1) | UA107571C2 (enExample) |
| WO (1) | WO2010115843A2 (enExample) |
| ZA (1) | ZA201107776B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US9605054B2 (en) * | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| EP3978517A1 (en) * | 2009-03-18 | 2022-04-06 | AC Immune SA | Method for therapeutic use |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CA3239368A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| EP2603233A1 (en) | 2010-08-12 | 2013-06-19 | AC Immune S.A. | Vaccine engineering |
| AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| PE20140218A1 (es) * | 2010-10-07 | 2014-03-01 | Ac Inmune S A | Composicion farmaceutica |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US9518101B2 (en) * | 2011-09-19 | 2016-12-13 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| ES2600915T3 (es) | 2011-10-07 | 2017-02-13 | Ac Immune S.A. | Anticuerpos fosfoespecíficos que reconocen Tau |
| EP2834270B1 (en) * | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| BR112014029566A2 (pt) * | 2012-05-31 | 2017-07-25 | Univ Osaka City | agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo |
| JP6345655B2 (ja) | 2012-07-03 | 2018-06-20 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | タウに対する抗体 |
| DK2885010T3 (da) | 2012-08-16 | 2020-02-03 | Ipierian Inc | Fremgangsmåder til behandling med tauopati |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| BR112015023262B8 (pt) * | 2013-03-15 | 2024-02-06 | Ac Immune Sa | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| SI3083680T1 (sl) | 2013-12-20 | 2020-06-30 | F. Hoffmann-La Roche Ag | Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| JP6913018B2 (ja) * | 2014-07-08 | 2021-08-04 | ニューヨーク・ユニバーシティ | タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用 |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
| CN107810196B (zh) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| MX2017015908A (es) | 2015-07-06 | 2018-03-15 | Ucb Biopharma Sprl | Anticuerpos de union a tau. |
| CN108135986B (zh) | 2015-08-13 | 2022-07-29 | 纽约大学 | 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 |
| EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| EP3548616A4 (en) | 2016-12-01 | 2020-05-13 | Sangamo Therapeutics, Inc. | TAU MODULATORS AND METHODS AND COMPOSITIONS FOR THEIR ADMINISTRATION |
| AR110321A1 (es) | 2016-12-07 | 2019-03-20 | Genentech Inc | Anticuerpos antitau y métodos de uso |
| KR20240035636A (ko) | 2016-12-07 | 2024-03-15 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| NZ762251A (en) | 2017-10-16 | 2025-12-19 | Eisai R&D Man Co Ltd | Anti-tau antibodies and uses thereof |
| EA202091012A1 (ru) * | 2017-10-25 | 2020-08-27 | Янссен Фармасьютикалз, Инк. | Композиции фосфорилированных тау-пептидов и их применения |
| CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
| CN113226333A (zh) | 2018-10-02 | 2021-08-06 | 桑格摩生物治疗股份有限公司 | 用于调控Tau蛋白的方法和组合物 |
| US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| CN113710269A (zh) | 2019-02-08 | 2021-11-26 | Ac免疫有限公司 | 磷酸化Tau肽疫苗的安全施用方法 |
| MA55902A (fr) * | 2019-04-24 | 2022-03-16 | Ac Immune Sa | Administration hétérologue de vaccins tau |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| EP4171633A1 (en) | 2020-06-25 | 2023-05-03 | Merck Sharp & Dohme LLC | High affinity antibodies targeting tau phosphorylated at serine 413 |
| WO2022144406A1 (en) * | 2020-12-29 | 2022-07-07 | Neurimmune Ag | Human anti-tau antibodies |
| US20250186580A1 (en) | 2022-02-28 | 2025-06-12 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
| KR102856378B1 (ko) * | 2022-09-30 | 2025-09-08 | 주식회사 젬백스앤카엘 | 4r 타우병증의 치료 또는 예방용 펩티드 |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| DK0673418T3 (da) | 1992-12-14 | 1999-03-01 | Innogenetics Nv | Monoklonale antistoffer rettet mod mikrotubulusassocieret tau-protein, hybridomaer, der secernerer disse antistoffer, antig |
| US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| MXPA00005494A (es) * | 1997-12-03 | 2003-05-19 | Curis Inc | Composiciones de proteina hidrofobicamente modificada y metodos. |
| JP2004503747A (ja) | 2000-07-11 | 2004-02-05 | モレキュラー ジェリアトリクス コーポレイション | 結合物質の同定するための試薬と方法 |
| WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20050261475A1 (en) * | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| SG172617A1 (en) | 2005-12-12 | 2011-07-28 | Ac Immune Sa | Therapeutic vaccine |
| WO2007068105A1 (en) * | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| EP2210901A4 (en) | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE |
| EP3978517A1 (en) * | 2009-03-18 | 2022-04-06 | AC Immune SA | Method for therapeutic use |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
-
2010
- 2010-01-04 UA UAA201112528A patent/UA107571C2/ru unknown
- 2010-04-01 WO PCT/EP2010/054418 patent/WO2010115843A2/en not_active Ceased
- 2010-04-01 HU HUE16179161A patent/HUE044981T2/hu unknown
- 2010-04-01 EP EP10713172.4A patent/EP2413957B1/en active Active
- 2010-04-01 DK DK16179161.1T patent/DK3097925T3/da active
- 2010-04-01 ES ES10713172.4T patent/ES2595371T3/es active Active
- 2010-04-01 KR KR1020157007957A patent/KR20150041203A/ko not_active Ceased
- 2010-04-01 SI SI201031297A patent/SI2413957T1/sl unknown
- 2010-04-01 MA MA34202A patent/MA34120B1/fr unknown
- 2010-04-01 SG SG2011071909A patent/SG175037A1/en unknown
- 2010-04-01 BR BRPI1015088-9A patent/BRPI1015088B1/pt active IP Right Grant
- 2010-04-01 AU AU2010233856A patent/AU2010233856B2/en active Active
- 2010-04-01 MX MX2011010353A patent/MX2011010353A/es active IP Right Grant
- 2010-04-01 CN CN201080024398.2A patent/CN102946899B/zh active Active
- 2010-04-01 HU HUE10713172A patent/HUE030428T2/en unknown
- 2010-04-01 CA CA2757345A patent/CA2757345C/en active Active
- 2010-04-01 KR KR1020117026246A patent/KR101770436B1/ko active Active
- 2010-04-01 JP JP2012502694A patent/JP5810076B2/ja active Active
- 2010-04-01 EP EP16179161.1A patent/EP3097925B1/en active Active
- 2010-04-01 RU RU2011144307/15A patent/RU2582916C2/ru active
- 2010-04-01 PT PT107131724T patent/PT2413957T/pt unknown
- 2010-04-01 PL PL16179161T patent/PL3097925T3/pl unknown
- 2010-04-01 NZ NZ595856A patent/NZ595856A/en unknown
- 2010-04-01 PT PT16179161T patent/PT3097925T/pt unknown
- 2010-04-01 DK DK10713172.4T patent/DK2413957T3/en active
- 2010-04-01 PL PL10713172T patent/PL2413957T3/pl unknown
- 2010-04-01 MY MYPI2011004748A patent/MY171300A/en unknown
- 2010-04-01 CN CN201510822296.XA patent/CN105524160B/zh active Active
- 2010-04-01 SI SI201031931T patent/SI3097925T1/sl unknown
- 2010-04-01 ES ES16179161T patent/ES2738623T3/es active Active
- 2010-04-01 US US13/262,793 patent/US8647631B2/en active Active
-
2011
- 2011-09-28 CR CR20110509A patent/CR20110509A/es unknown
- 2011-09-30 CO CO11129267A patent/CO6390113A2/es not_active Application Discontinuation
- 2011-10-02 IL IL215451A patent/IL215451A/en active IP Right Grant
- 2011-10-03 CL CL2011002457A patent/CL2011002457A1/es unknown
- 2011-10-03 EC ECSP11011367 patent/ECSP11011367A/es unknown
- 2011-10-24 ZA ZA2011/07776A patent/ZA201107776B/en unknown
-
2013
- 2013-09-16 US US14/028,415 patent/US20140255412A1/en not_active Abandoned
- 2013-10-08 CL CL2013002888A patent/CL2013002888A1/es unknown
-
2014
- 2014-12-19 US US14/577,325 patent/US20150259406A1/en not_active Abandoned
-
2015
- 2015-06-29 JP JP2015129383A patent/JP2015214559A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7539446B2 (ja) | 病理学的タウタンパク質の免疫学的標的化方法 | |
| JP6174727B2 (ja) | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 | |
| RU2011144307A (ru) | Фармацевтическая композиция | |
| JP2010530227A (ja) | モノクローナル抗βアミロイド抗体 | |
| JP2011522842A (ja) | パーキンソン病に関連する症状の治療のための化合物 | |
| AU2012244075B2 (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| AU2015201763A1 (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1204579B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1124532A (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1161141B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties | |
| HK1124532B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| HK1127486B (zh) | 治疗性疫苗 | |
| HK1127486A1 (en) | Therapeutic vaccine |